• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

7 months ago
R&D

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

7 months ago
R&D
Manufacturing

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

7 months ago
Pharma
FDA+

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

7 months ago
Pharma
FDA+

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

7 months ago
FDA+

BioN­Tech eas­es 2024 rev­enue out­look de­spite hefty Covid vac­cine third-quar­ter sales

7 months ago
Pharma

FDA ex­pands faster drug re­view pi­lot from sup­ple­men­tal to full ap­pli­ca­tions

7 months ago
Pharma
FDA+

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

7 months ago
R&D
Pharma

No­vo, As­cendis to work on month­ly GLP-1; KalVista makes a roy­al­ty deal

7 months ago
News Briefing

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

7 months ago
R&D
Pharma

Is there room for MASH drugs in a GLP-1 world?

7 months ago
R&D
Pharma

Eu­ro­pean Com­mis­sion marks Dec. 6 for No­vo-Catal­ent deal de­ci­sion

7 months ago
Deals
Manufacturing

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

7 months ago
R&D
Pharma

No­vo adds to We­govy’s car­dio strength with hos­pi­tal ad­mis­sions analy­sis

7 months ago
Pharma

Cin­Rx touts pos­i­tive ear­ly-stage da­ta from two obe­si­ty can­di­dates

7 months ago
R&D

How RFK Jr. might in­flu­ence the FDA; Phar­ma's Q3 high­lights; Ab­b­Vie's lat­est neu­ro buy­out; and more

7 months ago
Weekly

BMS, J&J and As­traZeneca plea with ap­peals court to over­turn drug price ne­go­ti­a­tions

7 months ago
Pharma
Law

Ex­clu­sive: Women’s health uni­corn Maven Clin­ic cuts 10% of its work­force weeks af­ter rais­ing $125M

7 months ago
People
Health Tech

Her­itage and Apo­tex to pay $49.1M in price-fix­ing set­tle­ment

7 months ago
Pharma
Law

No­vo Nordisk claims late-stage MASH vic­to­ry, con­tin­u­ing GLP-1's ex­pan­sion

7 months ago
R&D

FDA re­moves hold on three CARs­gen CAR-T tri­als; Ono pass­es on itolizum­ab

7 months ago
News Briefing

Ex­clu­sive: Blood stem cell ther­a­py mak­er Garu­da gets new CEO, adds $47M

7 months ago
Financing
Cell/Gene Tx

Bax­ter pulls IV prod­ucts out of Chi­na to shift sup­ply to the US

7 months ago
China
Manufacturing

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

7 months ago
R&D
First page Previous page 81828384858687 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times